Aevi Genomic Medicine Inc (GNMX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aevi Genomic Medicine Inc (GNMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3417
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company provides pipeline products such as AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glutamatergic neuromodulator, which is in Phase II and III SAGA trial for adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network. Aevi’s product candidate AEVI-002, is an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. It collaborates with other research institutes and companies. Aevi is headquartered in Wayne, Pennsylvania, the US.

Aevi Genomic Medicine Inc (GNMX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aevi Genomic Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Aevi Genomic Medicine Expands its Agreement with Kyowa Hakko Kirin 12
Medgenics Enters into Agreement with Harvard University 13
Licensing Agreements 14
NeuroFix Therapeutics Enters into Licensing Agreement with Lipopharma Therapeutics 14
Medgenics Enters into Licensing Agreement with Stanford University 15
Aevi Genomic Medicine Amends Licensing Agreement with Children’s Hospital of Philadelphia 16
Equity Offering 17
Aevi Genomic Medicine Plans to Raise up to USD20 Million in Public Offering of Shares 17
Aevi Genomic Medicine Plans to Raise Funds in Secondary Offering of Shares 18
Aevi Genomic Medicine to Raise USD28 Million in Private Placement of Shares and Warrrants 19
Medgenics Raises USD20 Million in Public Offering of Shares 20
Medgenics Raises USD46 Million in Public Offering of Shares 22
Medgenics Raises USD24.2 Million in Public Offering of Shares 24
Medgenics Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$32.5 Million 26
Medgenics Completes Private Placement Of Units For US$9.5 Million 28
Acquisition 29
Medgenics Acquires NeuroFix Therapeutics 29
Aevi Genomic Medicine Inc – Key Competitors 30
Aevi Genomic Medicine Inc – Key Employees 31
Aevi Genomic Medicine Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 02, 2018: Aevi Genomic Medicine reports second quarter 2018 financial results and provides business update 33
May 15, 2018: Aevi Genomic Medicine Reports First Quarter 2018 Financial Results and Provides Business Update 35
Mar 13, 2018: Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 36
Nov 02, 2017: Aevi Genomic Medicine Reports Third Quarter 2017 Financial Results 37
Aug 09, 2017: Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results 38
May 10, 2017: Aevi Genomic Medicine Announces First Quarter 2017 Operating Results 39
May 10, 2017: Aevi Genomic Medicine Q1 net loss decreases 40
Mar 09, 2017: Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 41
Corporate Communications 43
Dec 04, 2017: Aevi Genomic Medicine Announces New Appointment to its Board of Directors 43
Product News 44
04/20/2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 44
04/12/2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 46
03/20/2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 47
01/04/2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents 49
Clinical Trials 50
Jun 12, 2018: Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD 50
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aevi Genomic Medicine Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aevi Genomic Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aevi Genomic Medicine Expands its Agreement with Kyowa Hakko Kirin 12
Medgenics Enters into Agreement with Harvard University 13
NeuroFix Therapeutics Enters into Licensing Agreement with Lipopharma Therapeutics 14
Medgenics Enters into Licensing Agreement with Stanford University 15
Aevi Genomic Medicine Amends Licensing Agreement with Children's Hospital of Philadelphia 16
Aevi Genomic Medicine Plans to Raise up to USD20 Million in Public Offering of Shares 17
Aevi Genomic Medicine Plans to Raise Funds in Secondary Offering of Shares 18
Aevi Genomic Medicine to Raise USD28 Million in Private Placement of Shares and Warrrants 19
Medgenics Raises USD20 Million in Public Offering of Shares 20
Medgenics Raises USD46 Million in Public Offering of Shares 22
Medgenics Raises USD24.2 Million in Public Offering of Shares 24
Medgenics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$32.5 Million 26
Medgenics Completes Private Placement Of Units For US$9.5 Million 28
Medgenics Acquires NeuroFix Therapeutics 29
Aevi Genomic Medicine Inc, Key Competitors 30
Aevi Genomic Medicine Inc, Key Employees 31
Aevi Genomic Medicine Inc, Subsidiaries 32

List of Figures
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aevi Genomic Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Aevi Genomic Medicine Inc (GNMX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Viridian Group Investments Ltd:企業の戦略的SWOT分析
    Viridian Group Investments Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Symbiotec Pharmalab Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Symbiotec Pharmalab Ltd (Symbiotec) is a medical laboratory that manufactures active pharmaceutical ingredients. The laboratory develops, produces and markets research-based cortico steroids and steroid-hormone APIs. Its cortico-steroids APIs include clobetasol propionate, betamethasone dipr …
  • Ralph Lauren Corp:企業の戦略・SWOT・財務分析
    Ralph Lauren Corp - Strategy, SWOT and Corporate Finance Report Summary Ralph Lauren Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • GSS Infotech Limited (GSS):企業の財務・戦略的SWOT分析
    GSS Infotech Limited (GSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Alnylam Pharmaceuticals Inc (ALNY)-製薬・医療分野:企業M&A・提携分析
    Summary Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiova …
  • Shandong Dongming Petrochemical Group Co Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Shandong Dongming Petrochemical Group Co Ltd (Dongming Petrochemical) is a chemicals manufacturing company that offers chemicals and petrochemicals. The group’s products include gasoline, diesel, LPG, solvent oil, liquid paraffin, polypropylene, high-grade road asphalt, petroleum refining pr …
  • Topy Industries Ltd:企業の戦略・SWOT・財務情報
    Topy Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Topy Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • TS Corp (001790):企業の財務・戦略的SWOT分析
    TS Corp (001790) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Equity Assurance plc:企業の戦略・SWOT・財務情報
    Equity Assurance plc - Strategy, SWOT and Corporate Finance Report Summary Equity Assurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Owensboro Municipal Utilities:発電所・企業SWOT分析
    Owensboro Municipal Utilities - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Univalor-製薬・医療分野:企業M&A・提携分析
    Summary Univalor is a university technology transfer organization which optimizes research outcomes by commercializing the technological innovations of researchers from academic institutions and health centers. The organization offers researcher services such as evaluating the technical feasibility …
  • Altana Ag
    Altana Ag - Strategy, SWOT and Corporate Finance Report Summary Altana Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Terna Energy SA (TENERGY):企業の財務・戦略的SWOT分析
    Terna Energy SA (TENERGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • J&P – Avax Sa:企業の戦略・SWOT・財務分析
    J&P - Avax Sa - Strategy, SWOT and Corporate Finance Report Summary J&P - Avax Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Balfour Beatty plc:企業の戦略・SWOT・財務情報
    Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report Summary Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Silence Therapeutics Plc (SLN):企業の財務・戦略的SWOT分析
    Summary Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company's pipeline products include SLN124, SLN500 and SLN360. Its SLN124 is developed for the treatment of cardiovascula …
  • Gildan Activewear Inc (GIL):企業の財務・戦略的SWOT分析
    Gildan Activewear Inc (GIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Commonwealth Edison Company:電力:M&Aディール及び事業提携情報
    Summary Commonwealth Edison Company (ComEd) a subsidiary of Exelon Corporation is an electric utility that is engaged in the distribution of electricity to home and business customers. The utility’s business activities include lighting, retro-commissioning, HVAC, new construction, custom projects, i …
  • Golden Valley Mines Ltd. (GZZ):企業の財務・戦略的SWOT分析
    Golden Valley Mines Ltd. (GZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • University of Southampton-製薬・医療分野:企業M&A・提携分析
    Summary University of Southampton (UOS) is an educational institute that offers undergraduate and postgraduate programs. The university offers educational programs across various disciplines including accounting and finance, acoustical engineering, aeronautics and astronautics, anthropology, archaeo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆